Bio-Gene Technology has expanded its capital raise to $2.775 million through a share placement priced at 2.5 cents, attaching options exercisable at 3.5 cents pending shareholder approval.
- Placement increased by $65,000 to $2.775 million
- Shares issued at $0.025 with one free option per two shares
- Options exercisable at $0.035, expiring October 2027
- Tranche 1 shares issued under ASX placement capacity
- Tranche 2 shares and options subject to shareholder approval
Placement Extended to $2.775 Million
Bio-Gene Technology Limited (ASX:BGT) has secured an additional $65,000 from sophisticated investors, lifting its total placement proceeds to $2.775 million. This top-up follows an earlier $2.71 million placement announced in late May, reflecting ongoing investor appetite at the 2.5-cent share price.
Structure of the Placement and Option Incentives
The placement involves issuing 111 million fully paid ordinary shares split between two tranches. Tranche 1, comprising 76.24 million shares, was issued within the company’s existing ASX Listing Rule 7.1 and 7.1A placement capacities. Tranche 2, involving approximately 34.76 million shares, awaits shareholder approval at an extraordinary general meeting expected around 31 July 2026.
Investors will also receive free attaching unlisted options on a one-for-two basis, exercisable at 3.5 cents and expiring on 15 October 2027. These options are contingent on shareholder approval at the upcoming EGM and represent a potential source of further capital if exercised.
Regulatory Compliance and Disclosure
Bio-Gene has complied with all relevant provisions of the Corporations Act 2001 and ASX Listing Rules in relation to the placement. The tranche 1 shares were issued without disclosure under Part 6D.2 of the Act, leveraging the company’s placement capacities. An Appendix 2A notice for the issued shares has been lodged with the ASX.
Implications for Bio-Gene’s Funding and Strategy
This capital raise builds on Bio-Gene’s recent funding activities aimed at advancing regulatory submissions and scaling production of its bio-insecticide products. The funds are expected to support ongoing toxicology studies for Flavocide and meet growing demand for Qcide insecticides, aligning with the company’s strategic push into global markets.
Bottom Line?
The forthcoming shareholder vote on tranche 2 shares and options will be pivotal, determining the full extent of Bio-Gene’s capital boost and potential dilution ahead of key commercial milestones.
Questions in the middle?
- Will shareholders endorse the tranche 2 shares and options at the upcoming EGM?
- How will the additional capital influence Bio-Gene’s regulatory and production timelines?
- What impact might the option exercise price have on future capital structure and investor returns?